Cerebral Palsy News

Multaq Attorneys : A low level, also considered a noninfectious level of HBV DNA, is defined as less than 10,000 copies/ml. These low HBV DNA levels are only detectable if a very sensitive laboratory assay known as the polymerase chain reaction (PCR) is used. The PCR assay has the ability to detect levels as low 200 copies/ml. (These test results are often reported in picograms per milliliters (pg/ml) lpg/ml =

280,0 copies/ml.) In situations where people with resolved hepatitis B experi­ence severe immune suppression, such as cancer chemotherapy or organ trans­plantation, chronic hepatitis B can be reactivated. This means that HBsAg will become positive again.

More information on Multaq Attorneys

More than 1 million people worldwide die each year from hepatitis B. So, why is it that some people can live a long healthy life with hepatitis B and others experience serious complications? Well, it has been demonstrated that there are many factors that influence the progression from a mild, innocuous illness to a grave outcome. These factors include advanced age, general poor health—tor ex­ample, depressed immune status such as additionally infection with HIV; the presence of advanced damage found on a liver biopsy sample; and the presence of markers of chronicity and active infectiousness, especially HBV DNA. Simi­larly, people who do not clear HBeAg (spontaneous remission) tend to have a more aggressive course than those who clear HBeAg. In fact, in some studies it has been shown that people who clear HBeAg rarely progress to cirrhosis. Fur­thermore, people who clear HBeAg. whether spontaneously or from treatment, have a decreased incidence of liver failure and an improved long-term survival rate. People who are additionally infected with the hepatitis delta virus (HDV) (see page 106) or the hepatitis C virus (see chapter 10) also have poorer prog­noses. In addition, it has been shown that the outcome of a person infected with HBV is highly dependent upon the stage at which she first obtained medical at­tention. Those people who have more advanced disease on liver biopsy samples when initially seen by a specialist have a shorter survival time. It has also been found that people with genotype C have a worse prognosis than those with other genotypes. Lastly, it has been demonstrated that people infected with HBV are more susceptible to the toxic effects of alcohol on the liver than are those with­out HBV. Therefore, it is important for people with chronic hepatitis B to avoid all intake of alcohol, as alcohol may worsen the course and accelerate the pro­gression of the disease. See chapter 17 for more information on

Information from other sources on Multaq Attorneys

The Long-term Prognosis for Those with Chronic Hepatitis B

The probability each year that a person with chronic hepatitis B will develop cir­rhosis is about 2 percent. However, different studies have reported rates varying from 0.1 to 10 percent per year. The cumulative probability of progression to cir­rhosis over five years is approximately 15 to 20 percent. After the development of cirrhosis, the probability of developing serious complications, such as decom­pensated cirrhosis, is about 2 to 10 percent each year. The five-year survival rate after cirrhosis has developed varies from 52 to 80 percent. However, if a person has decompensated cirrhosis, the five-year survival rate decreases to between 14 and 35 percent.

Our use of the term or terms Multaq Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Attorneys visit our site often.

http://www.seedol.com

Multaq Attorneys : A low level, also considered a noninfectious level of HBV DNA, is defined as less than 10,000 copies/ml. These low HBV DNA levels are only detectable if a very sensitive laboratory assay known as the polymerase chain reaction (PCR) is used. The PCR assay has the ability to detect levels as low 200 copies/ml. (These test results are often reported in picograms per milliliters (pg/ml) lpg/ml =

280,0 copies/ml.) In situations where people with resolved hepatitis B experi­ence severe immune suppression, such as cancer chemotherapy or organ trans­plantation, chronic hepatitis B can be reactivated. This means that HBsAg will become positive again.

More information on Multaq Attorneys

More than 1 million people worldwide die each year from hepatitis B. So, why is it that some people can live a long healthy life with hepatitis B and others experience serious complications? Well, it has been demonstrated that there are many factors that influence the progression from a mild, innocuous illness to a grave outcome. These factors include advanced age, general poor health—tor ex­ample, depressed immune status such as additionally infection with HIV; the presence of advanced damage found on a liver biopsy sample; and the presence of markers of chronicity and active infectiousness, especially HBV DNA. Simi­larly, people who do not clear HBeAg (spontaneous remission) tend to have a more aggressive course than those who clear HBeAg. In fact, in some studies it has been shown that people who clear HBeAg rarely progress to cirrhosis. Fur­thermore, people who clear HBeAg. whether spontaneously or from treatment, have a decreased incidence of liver failure and an improved long-term survival rate. People who are additionally infected with the hepatitis delta virus (HDV) (see page 106) or the hepatitis C virus (see chapter 10) also have poorer prog­noses. In addition, it has been shown that the outcome of a person infected with HBV is highly dependent upon the stage at which she first obtained medical at­tention. Those people who have more advanced disease on liver biopsy samples when initially seen by a specialist have a shorter survival time. It has also been found that people with genotype C have a worse prognosis than those with other genotypes. Lastly, it has been demonstrated that people infected with HBV are more susceptible to the toxic effects of alcohol on the liver than are those with­out HBV. Therefore, it is important for people with chronic hepatitis B to avoid all intake of alcohol, as alcohol may worsen the course and accelerate the pro­gression of the disease. See chapter 17 for more information on

Information from other sources on Multaq Attorneys

The Long-term Prognosis for Those with Chronic Hepatitis B

The probability each year that a person with chronic hepatitis B will develop cir­rhosis is about 2 percent. However, different studies have reported rates varying from 0.1 to 10 percent per year. The cumulative probability of progression to cir­rhosis over five years is approximately 15 to 20 percent. After the development of cirrhosis, the probability of developing serious complications, such as decom­pensated cirrhosis, is about 2 to 10 percent each year. The five-year survival rate after cirrhosis has developed varies from 52 to 80 percent. However, if a person has decompensated cirrhosis, the five-year survival rate decreases to between 14 and 35 percent.

Our use of the term or terms Multaq Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Attorneys visit our site often.

http://www.seedol.com

Multaq Attorneys : In addition, these people are at risk for reactivation of the virus—return of HBeAg positivity. This occurs approximately 20 to 30 percent of the time. An in­dividual’s likelihood of reactivation increases if their immune system becomes suppressed. Such an occurrence may happen during treatment with immunosup­pressive drugs, such as steroids (prednisone, for example), or during a severe ill­ness, such as AIDS or cancer. Inactive carriers can also have flares of hepatitis. This may occur with or without the return of HBeAg and is noted by elevations in liver enzymes to approximately five to ten times the upper limit of normal. Repeated flares may lead to disease progression, liver scarring, and even liver failure.

Acute flares of hepatitis B should be distinguished from additional infection with hepatitis A, C, or D. Infection with an additional hepatitis virus is known as superinfection. It has been estimated that approximately 20 to 30 percent of such flares are due to superinfection with another hepatitis virus. Superinfection is as­sociated with an increased risk of liver failure.

More information on Multaq Attorneys

Chronic Hepatitis B

The second type of chronic hepatitis B is termed chronic hepatitis B and is found in a person who, in addition to carrying the HBsAg, also carries HBV DNA. The presence of detectable levels of HBV DNA indicates that a person is highly con­tagious or infectious to others. People with chronic hepatitis B may be either pos­itive or negative for HBeAg. In both HBeAg positive and HBeAg negative people, liver enzymes are either persistently or intermittently elevated, and liver biopsy results typically reveal inflammation and damage. People with chronic hepatitis are likely to have a progressive disease leading to cirrhosis.

Information from other sources on Multaq Attorneys

Chronic Hepatitis B—HBeAg positive

People with HBeAg positive chronic hepatitis B have only an 8 to 15 percent probability each year of becoming negative for HBeAg and HBV DNA. This is known as a spontaneous remission. When this happens, temporary gross eleva­tion in transaminases (AST and ALT) is observed, followed by a rapid return to normal levels. Antibodies to HBeAg (known as HBeAb) are formed. This is known as seroconversion. These people are no longer contagious to others and they experience minimal, if any. liver damage going forward. In fact, any past liver damage often resolves within the next few years. This resolution confirms the transition from chronic hepatitis B into the inactive HBsAg carrier state, as discussed above. Women, older people, and those individuals with genotype B are likeliest to seroconvert. Unfortunately, reactivation to the infectious state can occur in some of these people. Thus, these people must be observed carefully, ft is not clear which factors play a role in causing some people to relapse into an in­fectious state. Certainly excessive alcohol intake may have a harmful effect on people with chronic hepatitis B. And it has been demonstrated that excessive iron intake may promote persistent HBV replication in some people. (Excessive iron in itself can damage the liver and may lead to cirrhosis and liver cancer. This is dis­cussed in more detail in chapters 18 and 23.) Therefore, people with chronic hep­atitis B are advised to refrain from alcohol intake and should avoid excess iron supplementation. Seroconverters whose immune systems subsequently become compromised are at risk for a relapse. Immune-system function can become im­paired by a number of factors, including infection with the human immunodefi­ciency virus (HIV), treatment with chemotherapeutic agents for cancer, or use of corticosteroids such as prednisone.

Our use of the term or terms Multaq Attorneys is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Multaq Attorneys visit our site often.

http://www.seedol.com